The End of the Vanity Board: Can Embedded Experts Save Failing Eye Trials?

BOSTON, MA – September 24, 2026 — In the high-stakes world of biotechnology, the journey from a promising laboratory molecule to a patient’s bedside is littered with expensive casualties. Nowhere is this more evident than in ophthalmology, where the gap between theoretical science and real-world clinical execution routinely derails sight-saving therapies. Now, Ora, the world’s largest ophthalmic-focused contract research organization, is attempting to bridge that divide with the launch of its Clinical Intelligence Committee (CIC).

Announced today, the CIC is a global network of 14 distinguished ophthalmic key opinion leaders. On its face, assembling a roster of prominent doctors is standard industry practice. However, this initiative represents a calculated evolution of the traditional Scientific Advisory Board (SAB)—a model that critics argue has become too academic, too slow, and dangerously detached from the operational realities of modern clinical trials.

By embedding world-renowned specialists directly into the architecture of a trial before a single patient is enrolled, the clinical research organization is betting it can eliminate the costly protocol amendments and recruitment bottlenecks that have long plagued the sector.

The Staggering Cost of Getting It Wrong

To understand why this structural shift matters, one must look at the quiet crisis occurring in Phase 2 clinical trials. This phase is notoriously known as the graveyard of drug development. Recent longitudinal data reveals that nearly 45 percent of Phase 2 and 3 retinal studies fail to meet their primary endpoints or are prematurely terminated. In complex indications like dry age-related macular degeneration and geographic atrophy, that attrition rate spikes to over 52 percent.

"For years, we have watched brilliant science die on the vine because an academic advisory board designed a trial that no real-world clinic could actually execute," noted one veteran life sciences venture capitalist who evaluates early-stage ophthalmic biotechs. "You end up with a protocol that looks beautiful in a peer-reviewed journal but requires patients to undergo impossible screening criteria or endure intolerable clinical visits."

The financial penalty for these miscalculations is severe. Industry research indicates that up to 79 percent of all clinical trials undergo at least one substantial protocol amendment. In Phase 2, a single amendment costs an average of $141,000 and delays the program by months. By Phase 3, that cost balloons to $535,000 per amendment. More than just capital, these delays cost patients time—a luxury that those facing progressive vision loss simply do not have.

Often, these amendments are driven by faulty initial inclusion and exclusion criteria or the selection of the wrong regulatory endpoint. For example, relying on traditional Best-Corrected Visual Acuity (BCVA) has proven notoriously insensitive to early disease progression in non-foveal geographic atrophy. Navigating the nuances between anatomical surrogate endpoints, like lesion growth rates, and functional visual measures requires a level of pragmatic foresight that standalone startup advisory boards frequently lack.

Rethinking the Scientific Advisory Board

Historically, emerging biopharmaceutical companies have rushed to assemble their own SABs to signal scientific credibility to investors. These boards are typically composed of brilliant bench scientists and academic theorists. But retaining these experts takes months of negotiating master services agreements, managing equity compensation, and navigating institutional red tape.

The new committee bypasses this friction by institutionalizing the advisory process. The inaugural roster includes heavyweights across the ophthalmic spectrum, from surgical glaucoma pioneer Dr. Iqbal "Ike" K. Ahmed to retinal clinical trial leader Dr. Carl D. Regillo. Crucially, the group also includes operational pragmatists, such as biostatistician Dale W. Usner and commercial strategist Susan Benton.

"The ophthalmology landscape is becoming increasingly complex," said Gus De Moraes, MD, PhD, MPH, Chief Medical Officer at Ora. "We created the Clinical Intelligence Committee to bring together some of the most respected experts in our field and give innovators direct access to practical, experience-based guidance when it matters most. Combined with Ora's development expertise, the CIC helps teams gain clarity, reduce risk, and make better decisions for patients."

This multidisciplinary approach addresses a critical blind spot in traditional drug development. A posterior segment drug might be highly effective for the retina but cause severe ocular surface toxicity. An advisory board stacked entirely with retina specialists might miss this anterior segment risk until it derails a Phase 3 trial. By mandating cross-disciplinary review, the committee is designed to catch these compounding variables early.

Navigating the Complexity of Modern Eye Care

The shift from acting as a mere execution vendor to an upstream strategic partner highlights a broader trend in the contract research market. While multinational generalist CROs treat eye care as just one division among many, specialized organizations are recognizing that upfront protocol pressure-testing is where the true value lies.

However, this integrated model is not without its skeptics. The consolidation of advisory power within the same entity responsible for running the trial raises questions about commercial impartiality. Critics might ask if an embedded committee would ever recommend a smaller, leaner trial design when the parent organization generates more revenue from managing larger, highly complex global studies.

To safeguard against these conflicts of interest, the committee operates under strict governance frameworks. Members are retained as external advisors rather than full-time employees, ensuring compliance with the Physician Payments Sunshine Act and institutional conflict-of-interest thresholds. Chinese-wall protocols and non-disclosure agreements are heavily enforced, allowing top-tier experts to advise on trial mechanics without compromising intellectual property or violating exclusivity agreements with competing pharmaceutical giants.

A New Blueprint for Biotech Innovators

The ultimate test of this new advisory framework will be its impact on trial velocity and patient access. The goal is to transform expert insight into actionable development guidance, shifting the industry away from reactive problem-solving and toward proactive protocol design.

"Some of the most important development decisions are made long before a trial begins," said John Trein, MD, Ora Therapeutic Lead, Posterior. "Choices around study design, endpoints, patient populations, and operational execution can ultimately shape the trajectory of an entire program. The strength of the Clinical Intelligence Committee is the diversity of experience around the table. Sponsors gain direct access to experts who can help identify opportunities, uncover risks, and refine strategies based on decades of clinical and development experience."

As novel gene therapies, advanced surgical devices, and AI-driven imaging endpoints redefine what is possible in eye care, the margin for error in clinical development continues to shrink. The days of relying on theoretical advice to navigate highly regulated, operationally intense clinical environments are ending. For the thousands of patients waiting for breakthroughs in glaucoma, macular degeneration, and rare inherited retinal diseases, this shift toward rigorous, execution-focused trial design is not just a corporate restructuring but a vital lifeline.